Amarin Announces US Patent 8,314,086 Award for Vascepa
Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that the U.S. Patent and Trademark Office (USPTO) has issued a patent covering Amarin's Vascepa® (icosapent ethyl) capsules based on U.S. Patent Application Serial No. 13/284,408. On September 6, 2012, Amarin announced the issuance of a Notice of Allowance for claims under this application. The newly issued patent, U.S. Patent No. 8,314,086, has a term that expires no earlier than in 2030. Amarin plans to list this patent in the U.S. Food and Drug Administration's Approved Drug Products with Therapeutic Equivalence Evaluations, or Orange Book.
"This patent issuance represents yet another step forward in Amarin's effort to protect the commercial potential of Vascepa," said Joseph Zakrzewski, Amarin's Chairman and Chief Executive Officer. "Amarin's goal is to protect the commercial potential of Vascepa to beyond 2030 through patent protection, regulatory exclusivity and trade secrets and by taking advantage of manufacturing barriers to entry."
Amarin now has nine U.S. patents either issued or allowed as well as over 30 additional patent applications currently in prosecution in the United States. Amarin is